Elderly AMD patients to test Easy-to-Use home vision tracker
NCT ID NCT07338513
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to see if elderly patients with age-related macular degeneration (AMD) find a new web-based eye-tracking system easy and acceptable to use at home. The system is designed to help patients monitor their vision without frequent clinic visits. Thirty patients aged 55 to 99 with stable wet AMD will use the tool and provide feedback through questionnaires. The goal is to understand what makes digital health tools more user-friendly for older adults.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jan 2026
An estimate. Start dates often move.
- Expected to finish
-
Sep 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients previously recruited with recurrent vision problems diagnosed with active Wet-AMD at the TTSH Specialist Outpatient Clinic.
- Ages
-
55 to 99 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Subjects in the age group ≥ 55 to 99 years old. 2. Both genders 3. Able to understand verbal spoken instructions in British/American English, Chinese or Bahasa Melayu and demonstrate device functionality and implementation. 4. Subjects undergoing treatment for Wet-AMD without any signs and symptoms of recurrence of active AMD (AMD recurrence: choroidal neovascularisation, intraretinal or subretinal fluid is present) with OCT lesion fluid volume more than 2mm2 or ILM height more than 300µm. 5. Ability to comply with the study protocol, in the investigator's judgment. 6. Subjects must be able to understand and provide informed consent. A signed informed consent form must be provided before any study assessments. Exclusion Criteria: 1. Unable to understand verbal spoken instructions and demonstrate device functionality and implementation. 2. Unable to turn on and connect their computer to the AVIGA platform independently. 3. Any ocular surgery in the previous 3 months, or vitrectomy in the previous 12 months 4. Any history of macular pathology unrelated to AMD affecting vision or contributing to the presence of intraretinal or subretinal fluid in the study eye 5. Any concurrent intraocular condition in the study eye that, in the opinion of the investigator, could either reduce the potential for visual improvement or require medical or surgical intervention during the study 6. Any prior or concomitant treatment for CNV or vitreomacular-interface abnormalities in the study eye. 7. History of idiopathic or autoimmune-associated uveitis in either eye 8. Active ocular inflammation or suspected or active ocular or periocular infection in either eye. 9. Severe cognitive impairment, comorbid conditions severely limiting participation (e.g., advanced hearing loss)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Age-related macular degeneration are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Tan Tock Seng Hospital
Singapore, 308433, Singapore
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could years of eye injections weigh down the upper eyelid?
- New eye drug goes Head-to-Head with standard treatment for wet AMD
- New eye drug goes Head-to-Head with standard care for wet AMD
- Eye drops could replace injections for wet AMD
- Can blocking rogue immune cells stop a leading cause of blindness?
- A window into the eye: could functional tests predict macular degeneration progression?